20 results
8-K
EX-99.2
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
a 3-point improvement in mADL11
14 Essential3: An innovative Phase 3 program that optimizes all aspects of study conduct Single Recruiting Expert
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
9 May 22
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:04pm
, and plans to accelerate development in the ongoing Essential1 study, we will soon have a second late-stage clinical asset along with a deep and innovative
8-K
EX-99.1
pzrrw3b
17 Dec 21
Regulation FD Disclosure
4:40pm
424B4
tcrx83dq67r8 yfkttb8
14 May 21
Prospectus supplement with pricing info
4:34pm
8-K
EX-99.1
odbkb3z9f 2hkbeqkl
29 Apr 21
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit
8:07am
DRS
3bp6786ri
18 Mar 21
Draft registration statement
12:00am
10-K
zgna7el1zn85iyd3 60
17 Mar 21
Annual report
8:33am
8-K
EX-99.1
k2oimy6 sx9b4i41
17 Mar 21
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
7:17am
424B4
aze06f99tydh
16 Oct 20
Prospectus supplement with pricing info
4:02pm
S-1
o076ik4d lgzhnao1
25 Sep 20
IPO registration
5:19pm
DRS/A
cwhrrhq eth
28 Aug 20
Draft registration statement (amended)
12:00am
DRS
y06ls48d184
22 Jul 20
Draft registration statement
12:00am
- Prev
- 1
- Next